MetaCap

Amylyx Pharmaceuticals (AMLX) vs Xenon Pharmaceuticals (XENE)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Amylyx Pharmaceuticals (AMLX) has outperformed Xenon Pharmaceuticals (XENE) over the past year, gaining 77.4% versus a loss of 10.0%. Xenon Pharmaceuticals is the larger company by market cap ($3.64 billion vs $3.35 billion), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

AMLX+77.37%XENE-10.01%
+180%+74%-32%
Nov 21, 20251 yearNov 20, 2026
AMLX+44.00%XENE+21.44%
+137%+18%-102%
Jan 3, 20225 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

AMLX versus XENE key metrics
MetricAMLXXENE
Share price$26.02$37.04
Market cap$3.35B$3.64B
1-day change-0.69%-1.38%
YTD return+115.40%-17.36%
1-year return+77.37%-10.01%
5-year return—+34.99%
EPS (TTM)$-1.43$-4.69
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$0$7.50M
Revenue growth (YoY)-100.00%—
Net income (latest FY)$-144.74M$-345.91M
Operating margin—-4974.27%
Net margin—-4612.13%
52-week high$41.14$72.66
52-week low$10.83$33.38
Distance from 52-week high-36.75%-49.02%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+65.26%+93.55%
Average volume1.53M1.69M
Shares outstanding128.56M98.28M
Employees136358
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • AMLX has outperformed XENE by 87.4 percentage points over the past year.

About Amylyx Pharmaceuticals

AMLX stock →

Amylyx Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, engages in the discovery and development of treatment options for neurodegenerative diseases and endocrine conditions in the United States. It provides Avexitide, an investigational, first-in-class glucagon-like peptide-1, or GLP-1 receptor antagonist, which is in phase 3 clinical trial to treat post-bariatric hypoglycemia and congenital hyperinsulinism.

Health Care · Biotechnology: Pharmaceutical Preparations · 136 employees

About Xenon Pharmaceuticals

XENE stock →

Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the discovery, development, and delivery of therapeutics to treat patients with neurological and psychiatric disorders. Its product candidates include Azetukalner, a novel, potent Kv7 potassium channel opener which is in Phase 3 clinical development for the treatment of epilepsy, including focal onset seizures, and primary generalized tonic-clonic seizures, as well as neuropsychiatric disorders, such as major depressive disorder and bipolar depression.

Health Care · Biotechnology: Pharmaceutical Preparations · 358 employees

AMLX vs XENE FAQ

Which is bigger, Amylyx Pharmaceuticals or Xenon Pharmaceuticals?

Xenon Pharmaceuticals (XENE) is larger, with a market capitalization of $3.64B compared with $3.35B for Amylyx Pharmaceuticals (AMLX).

Which stock has performed better over the past year, AMLX or XENE?

AMLX returned +77.37% over the past 12 months, compared with -10.01% for XENE (price return, excluding dividends). Past performance does not predict future results.

Are Amylyx Pharmaceuticals and Xenon Pharmaceuticals in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons